Abstract 4511
Background
In the Phase III POLO trial (NCT02184195) patients (pts) with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and mPC derived a statistically significant and clinically meaningful progression-free survival benefit from maintenance olaparib compared with placebo. HRQoL assessment was a predefined secondary objective.
Methods
Pts with a gBRCAm and mPC whose disease had not progressed during first-line platinum-based chemotherapy were randomized to receive maintenance olaparib tablets (300 mg bid) or placebo. Pts completed the EORTC QLQ-C30 questionnaire at baseline and every 4 wks until discontinuation, with calculated scores ranging from 1–100. A change of ≥ 10 points was predefined as clinically meaningful improvement (increase) or deterioration (decrease) for global HRQoL and physical function score. Overall adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TCMD) was analysed using a log-rank test.
Results
Analyses were conducted in 89/92 olaparib pts and 58/62 placebo pts with evaluable baseline forms (overall compliance was 96.6% and 94.8%). There was no difference between arms for global HRQoL score (Table). The adjusted mean difference for physical function scale did not reach the threshold considered to be clinically meaningful. Global HRQoL and physical function remained relatively stable over time. There was no difference in TCMD for olaparib versus placebo for global HRQoL (median 21.2 vs 6.0 mo, respectively; hazard ratio 0.72 [95% CI 0.41–1.27]) or physical function (medians not reached, 1.38 [0.73–2.63]).Table:
675PD
Global HRQoL | Physical function | |||
---|---|---|---|---|
Maintenance olaparib | Placebo | Maintenance olaparib | Placebo | |
Absolute score, mean (n) | ||||
Baseline | 70.4 (89) | 74.3 (58) | 83.3 (89) | 84.9 (58) |
Week 12 | 73.6 (66) | 74.1 (36) | 84.4 (67) | 85.4 (36) |
Week 24 | 73.4 (41) | NC | 87.4 (43) | NC |
Week 48 | 79.0 (23) | NC | 89.6 (23) | NC |
Overall change from baseline* | ||||
Adjusted mean ± SE (n) | −1.2±1.4 (84) | 1.3±1.9 (54) | −2.1±1.3 (84) | 2.4± 1.7 (54) |
Between group difference (95% CI) | −2.5 (−7.3, 2.3) | −4.5 (−8.7, −0.2) | ||
P value | 0.31 | 0.04 |
Pts had to have baseline and ≥1 post-baseline assessment
NC, not calculated due to insufficient numbers of values; SE, standard error
Conclusions
HRQoL was preserved during maintenance olaparib treatment with no meaningful difference versus placebo. Findings support the observed clinical benefit of maintenance olaparib in pts with a gBRCAm and mPC.
Clinical trial identification
NCT02184195.
Editorial acknowledgement
Debbi Gorman, from Mudskipper Business, Ltd, funded by AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A.
Legal entity responsible for the study
AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A.
Funding
AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A.
Disclosure
P. Hammel: Research grant / Funding (institution): Celgene; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution), Non-remunerated activity/ies: Erythec; Honoraria (self), Research grant / Funding (institution): Halozyme. H.L. Kindler: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Advisory / Consultancy: Aldeyra Therapeutics; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer-Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Erytech; Advisory / Consultancy: Five Prime Therapeutics; Advisory / Consultancy: Ipsen Pharmaceuticals; Advisory / Consultancy: Kyowa; Advisory / Consultancy, Travel / Accommodation / Expenses: Paredox Therapeutics; Research grant / Funding (institution): Aduro; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Polaris; Research grant / Funding (institution): Verastem. M. Reni: Honoraria (self), Research grant / Funding (institution), Non-remunerated activity/ies: Celgene; Honoraria (self): Baxalta; Honoraria (self): Shire; Honoraria (self): Eli-Liily; Honoraria (self): Pfizer; Honoraria (self): Novocure; Honoraria (self): Novartis; Advisory / Consultancy, Steering committee member: AstraZeneca; Advisory / Consultancy, Steering committee member: Boston Pharmaceuticals. E. Van Cutsem: Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bristol-Myers Squibb. T. Macarulla Mercade: Advisory / Consultancy: Genzyme; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi Aventis; Advisory / Consultancy: Shire; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Baxalta; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Travel / Accommodation / Expenses: H3 Biomedicine; Advisory / Consultancy: QED Therapeutics; Research grant / Funding (institution): Agios pharmaceuticals, Aslan pharmaceuticals; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Halozyme, Inc, Immunomedics, Merrimack, Millennium; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Novartis Farmaceutica S.A.; Research grant / Funding (institution): Novocure GmBH; Research grant / Funding (institution): Oncomed, Pharmacyclics; Research grant / Funding (institution): Pfizer S.L.U.; Travel / Accommodation / Expenses: Merck. M.J. Hall: Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: AstraZeneca; Travel / Accommodation / Expenses, Non-remunerated activity/ies, Non-remunerated activities relate to collaborative research: Caris Life Sciences; Non-remunerated activity/ies, Collaborative research: Myriad; Non-remunerated activity/ies, Collaborative research: Ambry; Non-remunerated activity/ies, Collaborative research: Invitae; Non-remunerated activity/ies, Collaborative research: Foundation Medicine; Non-remunerated activity/ies: Merck. J.O. Park: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Celgene; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Shire; Advisory / Consultancy: Merck; Advisory / Consultancy: Sereno. D. Arnold: Honoraria (self): AstraZeneca; Honoraria (self), Non-remunerated activity/ies: Bayer; Honoraria (self), Non-remunerated activity/ies: Bristol-Myers Squibb; Honoraria (self): Biocompatibles; Honoraria (self): Eli Lilly; Honoraria (self), Non-remunerated activity/ies: Merck Sharpe & Dohme; Honoraria (self), Non-remunerated activity/ies: Servier; Honoraria (self), Non-remunerated activity/ies: Sanofi; Honoraria (self), Non-remunerated activity/ies: Roche; Honoraria (self): Terumo; Honoraria (self): Sirtex. D. Oh: Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Novartis; Advisory / Consultancy: Genentech/ Roche; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Bayer; Advisory / Consultancy: Taiho; Advisory / Consultancy: Aslan; Advisory / Consultancy: Halozyme. A. Reinacher-Schick: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: Baxalta; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Research grant / Funding (institution): Ipsen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy: Merck Sharpe & Dohme; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy: Sanofi-Aventis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Servier; Research grant / Funding (institution): AstraZeneca. G. Tortora: Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis. H. Algül: Honoraria (self): Celgene; Honoraria (self), Travel / Accommodation / Expenses: Servier; Research grant / Funding (institution): Chugai. E.M. O’Reilly: Advisory / Consultancy, Including spouse: 3DMedcare, Boston Scientific, CytomX, Daiichi, Debio, Delcath, Exelixis, Alignmed, Antengene, Aptus, Beigene, Bioline, Bridgebio, Carsgen, Aslan, Genoscience, Hengrui Inovio, LAM, Loxo, Mina, Novella, Onxeo, PCI Biotech, Pieris, QED, Redhill, Silenseed,; Research grant / Funding (institution), Including spouse: Actabiologica, Incyte, Array, Celgene, Mabvax, Oncoquest, Polaris, Puma; Advisory / Consultancy, Research grant / Funding (institution), Including spouse: Agios, Halozyme, Casi; Advisory / Consultancy, Including spouse: Amgen; Advisory / Consultancy, Including spouse: Astellas; Advisory / Consultancy, Research grant / Funding (institution), Including spouse: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Including spouse: Bayer; Advisory / Consultancy, Research grant / Funding (institution), Including spouse: BMS; Advisory / Consultancy, Including spouse: Eisai; Research grant / Funding (institution), Including spouse: Genentech; Advisory / Consultancy, Including spouse: Ipsen; Advisory / Consultancy, Including spouse: Jazz; Advisory / Consultancy, Including spouse: Janssen; Advisory / Consultancy, Including spouse: Kyowa Kirin; Advisory / Consultancy, Research grant / Funding (institution), Including spouse: Lilly; Advisory / Consultancy, Including spouse: Merck; Research grant / Funding (institution), Including spouse: Novartis; Advisory / Consultancy, Including spouse: Pfizer; Research grant / Funding (institution), Including spouse: Roche; Advisory / Consultancy, Including spouse: Sanofi; Advisory / Consultancy, Including spouse: Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vicus, Yakult, Yiviva. D. McGuinness: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. K.Y. Cui: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. S. Joo: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. H.K. Yoo: Full / Part-time employment: AstraZeneca. N. Patel: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. T. Golan: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Merck Sharp & Dohme Corp; Honoraria (self): AbbVie; Honoraria (self): Teva. All other authors have declared no conflicts of interest.
Resources from the same session
3222 - Nab-paclitaxel (Nab) plus Gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): the GAP trial, a GISCAD phase II comparative randomized trial.
Presenter: Stefano Cascinu
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5184 - Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): safety and biomarker data from the ICONIC trial safety run-in
Presenter: Michael Davidson
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4623 - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Presenter: Philippe Merle
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3561 - Comprehensive Genomic Profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)
Presenter: Karthikeyan Murugesan
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4537 - Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Presenter: Lorenza Rimassa
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3521 - Large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)
Presenter: Jingyuan Wang
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1484 - Genomic alterations predict clinical response to systemic chemotherapy and immune checkpoint blockade in biliary tract cancer
Presenter: Min Hwan Kim
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1438 - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study
Presenter: Luis Garcia Rodriguez
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4638 - Health-Related Quality of Life (HRQoL) Impact of Pembrolizumab (P) Versus Chemotherapy (C) as First-Line (1L) Treatment in PD-L1–Positive Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Presenter: Eric Van Cutsem
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5708 - Chemotherapy for Frail and Elderly Patients (pts) with Advanced Gastroesophageal Cancer (aGOAC): Quality of Life (QoL) results from the GO2 Phase III Trial
Presenter: Peter Hall
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract